vs
Apellis Pharmaceuticals, Inc.（APLS）与Mission Produce, Inc.（AVO）财务数据对比。点击上方公司名可切换其他公司
Mission Produce, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$319.0M vs $199.9M），Mission Produce, Inc.净利率更高（5.0% vs -29.5%，领先34.5%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -10.0%），Mission Produce, Inc.自由现金流更多（$55.6M vs $-14.3M），过去两年Mission Produce, Inc.的营收复合增速更高（11.0% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
根据现有信息，该描述将Mission Produce, Inc.错误混淆为一家日本电子游戏企业。原描述提及这家企业由前IREM员工于1990年4月6日创立，曾为艾尼克斯、哈德森开发多款游戏，作品覆盖街机、超级任天堂、Nintendo 64、PlayStation等多个平台。
APLS vs AVO — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $319.0M |
| 净利润 | $-59.0M | $16.0M |
| 毛利率 | — | 17.5% |
| 营业利润率 | -25.6% | 8.8% |
| 净利率 | -29.5% | 5.0% |
| 营收同比 | -5.9% | -10.0% |
| 净利润同比 | -62.2% | -7.5% |
| 每股收益（稀释后） | $-0.40 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $319.0M | ||
| Q3 25 | $458.6M | $357.7M | ||
| Q2 25 | $178.5M | $380.3M | ||
| Q1 25 | $166.8M | $334.2M | ||
| Q4 24 | $212.5M | $354.4M | ||
| Q3 24 | $196.8M | $324.0M | ||
| Q2 24 | $199.7M | $297.6M | ||
| Q1 24 | $172.3M | $258.7M |
| Q4 25 | $-59.0M | $16.0M | ||
| Q3 25 | $215.7M | $14.7M | ||
| Q2 25 | $-42.2M | $3.1M | ||
| Q1 25 | $-92.2M | $3.9M | ||
| Q4 24 | $-36.4M | $17.3M | ||
| Q3 24 | $-57.4M | $12.4M | ||
| Q2 24 | $-37.7M | $7.0M | ||
| Q1 24 | $-66.4M | $0 |
| Q4 25 | — | 17.5% | ||
| Q3 25 | — | 12.6% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | 10.4% | ||
| Q1 24 | — | 11.1% |
| Q4 25 | -25.6% | 8.8% | ||
| Q3 25 | 48.7% | 5.9% | ||
| Q2 25 | -18.6% | 1.8% | ||
| Q1 25 | -50.0% | 2.8% | ||
| Q4 24 | -12.3% | 8.1% | ||
| Q3 24 | -24.0% | 5.2% | ||
| Q2 24 | -14.7% | 4.1% | ||
| Q1 24 | -36.0% | 3.1% |
| Q4 25 | -29.5% | 5.0% | ||
| Q3 25 | 47.0% | 4.1% | ||
| Q2 25 | -23.6% | 0.8% | ||
| Q1 25 | -55.3% | 1.2% | ||
| Q4 24 | -17.1% | 4.9% | ||
| Q3 24 | -29.2% | 3.8% | ||
| Q2 24 | -18.9% | 2.4% | ||
| Q1 24 | -38.5% | — |
| Q4 25 | $-0.40 | $0.23 | ||
| Q3 25 | $1.67 | $0.21 | ||
| Q2 25 | $-0.33 | $0.04 | ||
| Q1 25 | $-0.74 | $0.05 | ||
| Q4 24 | $-0.30 | $0.25 | ||
| Q3 24 | $-0.46 | $0.17 | ||
| Q2 24 | $-0.30 | $0.10 | ||
| Q1 24 | $-0.54 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $64.8M |
| 总债务越低越好 | — | $95.8M |
| 股东权益账面价值 | $370.1M | $587.3M |
| 总资产 | $1.1B | $983.0M |
| 负债/权益比越低杠杆越低 | — | 0.16× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $64.8M | ||
| Q3 25 | $479.2M | $43.7M | ||
| Q2 25 | $370.0M | $36.7M | ||
| Q1 25 | $358.4M | $40.1M | ||
| Q4 24 | $411.3M | $58.0M | ||
| Q3 24 | $396.9M | $49.5M | ||
| Q2 24 | $360.1M | $46.2M | ||
| Q1 24 | $325.9M | $39.9M |
| Q4 25 | — | $95.8M | ||
| Q3 25 | — | $131.5M | ||
| Q2 25 | — | $147.2M | ||
| Q1 25 | — | $117.9M | ||
| Q4 24 | — | $113.7M | ||
| Q3 24 | — | $134.4M | ||
| Q2 24 | — | $170.2M | ||
| Q1 24 | $93.1M | $156.1M |
| Q4 25 | $370.1M | $587.3M | ||
| Q3 25 | $401.2M | $568.7M | ||
| Q2 25 | $156.3M | $552.3M | ||
| Q1 25 | $164.2M | $550.8M | ||
| Q4 24 | $228.5M | $547.3M | ||
| Q3 24 | $237.1M | $527.3M | ||
| Q2 24 | $264.3M | $513.3M | ||
| Q1 24 | $266.7M | $505.1M |
| Q4 25 | $1.1B | $983.0M | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $821.4M | $1.0B | ||
| Q1 25 | $807.3M | $997.8M | ||
| Q4 24 | $885.1M | $971.5M | ||
| Q3 24 | $901.9M | $959.9M | ||
| Q2 24 | $904.5M | $966.9M | ||
| Q1 24 | $831.9M | $937.5M |
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.21× | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | 0.25× | ||
| Q2 24 | — | 0.33× | ||
| Q1 24 | 0.35× | 0.31× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $67.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $55.6M |
| 自由现金流率自由现金流/营收 | -7.1% | 17.4% |
| 资本支出强度资本支出/营收 | 0.1% | 3.6% |
| 现金转化率经营现金流/净利润 | — | 4.20× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $37.2M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $67.2M | ||
| Q3 25 | $108.5M | $34.4M | ||
| Q2 25 | $4.4M | $-11.8M | ||
| Q1 25 | $-53.4M | $-1.2M | ||
| Q4 24 | $19.4M | $38.0M | ||
| Q3 24 | $34.1M | $42.5M | ||
| Q2 24 | $-8.3M | $3.4M | ||
| Q1 24 | $-133.0M | $9.5M |
| Q4 25 | $-14.3M | $55.6M | ||
| Q3 25 | $108.3M | $22.6M | ||
| Q2 25 | $4.4M | $-25.0M | ||
| Q1 25 | $-53.4M | $-16.0M | ||
| Q4 24 | $19.3M | $31.1M | ||
| Q3 24 | — | $34.9M | ||
| Q2 24 | $-8.4M | $-4.4M | ||
| Q1 24 | $-133.3M | $-400.0K |
| Q4 25 | -7.1% | 17.4% | ||
| Q3 25 | 23.6% | 6.3% | ||
| Q2 25 | 2.5% | -6.6% | ||
| Q1 25 | -32.0% | -4.8% | ||
| Q4 24 | 9.1% | 8.8% | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | -4.2% | -1.5% | ||
| Q1 24 | -77.3% | -0.2% |
| Q4 25 | 0.1% | 3.6% | ||
| Q3 25 | 0.0% | 3.3% | ||
| Q2 25 | 0.0% | 3.5% | ||
| Q1 25 | 0.0% | 4.4% | ||
| Q4 24 | 0.0% | 1.9% | ||
| Q3 24 | 0.0% | 2.3% | ||
| Q2 24 | 0.0% | 2.6% | ||
| Q1 24 | 0.2% | 3.8% |
| Q4 25 | — | 4.20× | ||
| Q3 25 | 0.50× | 2.34× | ||
| Q2 25 | — | -3.81× | ||
| Q1 25 | — | -0.31× | ||
| Q4 24 | — | 2.20× | ||
| Q3 24 | — | 3.43× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
AVO
| Avocado | $256.9M | 81% |
| Blueberry | $36.5M | 11% |
| Mango | $18.7M | 6% |
| Other | $6.9M | 2% |
